荧光引导立体定向活检:一项概念验证研究
该研究将直径0.65毫米相干光纤荧光微内窥镜与立体定向活检系统耦合,在植入U251-BFP胶质瘤细胞的转基因无胸腺大鼠(n=4)中,于活检前进行体内荧光成像。结果显示肿瘤区域荧光强度显著高于对侧正常脑组织(301.7 ± 34.18相对荧光单位,p < 0.001),但肿瘤边缘与正常脑组织无显著差异(p = 0.89)。作者认为体内荧光引导可能提高立体定向活检的诊断率。
要点
- 光纤荧光微内窥镜与立体定向活检针耦合,可在活检前直接可视化肿瘤组织。
- 肿瘤区域荧光强度显著高于对侧正常脑组织(p < 0.001)。
- 肿瘤边缘荧光强度与正常脑组织无显著差异(p = 0.89)。
核心结论
- 作者发现,在动物脑肿瘤模型中,将亚毫米直径光纤荧光微内窥镜置入立体定向活检针进行体内荧光成像,可在活检前直接可视化肿瘤组织。
- 这些结果通过阳性对照细胞和事后组织学评估在体内得到证实。
- 作者认为体内荧光引导可能提高立体定向活检的诊断率。
研究设计与样本
- 研究开发了一种微创光纤成像系统,将直径0.65毫米的相干光纤荧光微内窥镜与立体定向活检系统耦合。
- 体外实验使用转导稳定表达蓝色荧光蛋白(BFP)的人U251胶质瘤细胞(U251-BFP),用荧光显微镜确认蓝色荧光并量化荧光素钠(FNa)对肿瘤细胞的勾勒。
- 体内实验使用植入U251-BFP细胞的转基因无胸腺大鼠(n = 4),植入后5周静脉给予5-10 mg/kg FNa,在肿瘤植入部位和对侧正常脑上方行开颅术。
- 将含有0.65毫米成像光纤的临床立体定向活检针通过每个开颅处,采集并量化肿瘤植入同侧和对侧感兴趣区的荧光图像。
主要发现
- 活细胞荧光成像确认转导肿瘤细胞发出蓝色荧光,蓝色荧光量化的肿瘤细胞与FNa对比度呈强相关(R2 = 0.91,p < 0.001)。
- 经背景归一化后,所有动物中肿瘤区域(经蓝色荧光验证)的体内FNa介导荧光强度显著高于对侧脑组织(301.7 ± 34.18相对荧光单位,p < 0.001)。
- 肿瘤边缘测量的荧光强度与正常脑组织相比无显著差异(p = 0.89)。
- 从强荧光素对比区域获取的活检组织学与肿瘤一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVEAccurate histopathological diagnoses are often necessary for treating neuro-oncology patients. However, stereotactic biopsy (STB), a common method for obtaining suspicious tissue from deep or eloquent brain regions, fails to yield diagnostic tissue in some cases. Failure to obtain diagnostic tissue can delay initiation of treatment and may result in further invasive procedures for patients. In this study, the authors sought to determine if the coupling of in vivo optical imaging with an STB system is an effective method for identification of diagnostic tissue at the time of biopsy.METHODSA minimally invasive fiber optic imaging system was developed by coupling a 0.65-mm-diameter coherent fiber optic fluorescence microendoscope to an STB system. Human U251 glioma cells were transduced for stable expression of blue fluorescent protein (BFP) to produce U251-BFP cells that were utilized for in vitro and in vivo experiments. In vitro, blue fluorescence was confirmed, and tumor cell delineation by fluorescein sodium (FNa) was quantified with fluorescence microscopy. In vivo, transgenic athymic rats implanted with U251-BFP cells (n = 4) were utilized for experiments. Five weeks postimplantation, the rats received 5-10 mg/kg intravenous FNa and underwent craniotomies overlying the tumor implantation site and contralateral normal brain. A clinical STB needle containing our 0.65-mm imaging fiber was passed through each craniotomy and images were collected. Fluorescence images from regions of interest ipsilateral and contralateral to tumor implantation were obtained and quantified.RESULTSLive-cell fluorescence imaging confirmed blue fluorescence from transduced tumor cells and revealed a strong correlation between tumor cells quantified by blue fluorescence and FNa contrast (R2 = 0.91, p < 0.001). Normalized to background, in vivo FNa-mediated fluorescence intensity was significantly greater from tumor regions, verified by blue fluorescence, compared to contralateral brain in all animals (301.7 ± 34.18 relative fluorescence units, p < 0.001). Fluorescence intensity measured from the tumor margin was not significantly greater than that from normal brain (p = 0.89). Biopsies obtained from regions of strong fluorescein contrast were histologically consistent with tumor.CONCLUSIONSThe authors found that in vivo fluorescence imaging with an STB needle containing a submillimeter-diameter fiber optic fluorescence microendoscope provided direct visualization of neoplastic tissue in an animal brain tumor model prior to biopsy. These results were confirmed in vivo with positive control cells and by post hoc histological assessment. In vivo fluorescence guidance may improve the diagnostic yield of stereotactic biopsies.
引用
- Lynagh R, Ishak M, Georges J, et al. Fluorescence-guided stereotactic biopsy: a proof-of-concept study. J Neurosurg. 2019. PMID: 30797218. doi:10.3171/2018.11.JNS18629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。